{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Albert Prats-Uribe, Spyros Kolovos, Klara Berencsi, Andrew Carr, Andrew Judge, Alan Silman, Nigel Arden, Irene Petersen, Ian J Douglas, J Mark Wilkinson, David Murray, Jose M Valderas, David J Beard, Sarah E Lamb, M Sanni Ali, Rafael Pinedo-Villanueva, Victoria Y Strauss & Daniel Prieto-Alhambra.

Albert Prats-Uribe ¹, Spyros Kolovos ¹, Klara Berencsi ¹, Andrew Carr ¹, Andrew Judge ^1,2, Alan Silman ¹, Nigel Arden ^1,3,4, Irene Petersen ⁵, Ian J Douglas ⁶, J Mark Wilkinson ^7,8, David Murray ¹, Jose M Valderas ⁹, David J Beard ¹, Sarah E Lamb ^1,10, M Sanni Ali ^1,6, Rafael Pinedo-Villanueva ¹, Victoria Y Strauss ^1,*, Daniel Prieto-Alhambra ¹

¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK
² Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Southmead Hospital, Bristol, UK
³ Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK
⁴ Medical Research Council Lifecourse Epidemiological Unit, University of Southampton, Southampton, UK
⁵ Department of Primary Care and Population Health, University College London, London, UK
⁶ Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
⁷ Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
⁸ Research Committee, National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, Hemel Hempstead, UK
⁹ College of Medicine and Health, University of Exeter, Exeter, UK
¹⁰ University of Exeter Medical School, Institute of Health Research, College of Medicine and Health, Exeter, UK
^* Corresponding author Email: Victoria.strauss@csm.ox.ac.uk

Declared competing interests of authors: Albert Prats-Uribe reports grants from Fundación Alfonso Martin Escudero (Madrid, Spain) and the Medical Research Council (London, UK). Andrew Judge was a sub-panel member of the National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) programme (September 2015–August 2020); has received personal fees from Freshfields Bruckhaus Deringer (London, UK); and was a member of the Data Safety and Monitoring Board (December 2012 to June 2016) (which involved receipt of fees) from Anthera Pharmaceuticals Inc. (Hayward, CA, USA). Nigel Arden reports grants from Merck & Co. Inc. (Darmstadt, Germany) and personal fees from Merck & Co. Inc., Flexion Therapeutics (Burlington, MA, USA), Regeneron (Tarrytown, NY, USA) and Pfizer Inc. (New York, NY, USA)/Eli Lilly and Company (Indianapolis, IN, USA) outside the submitted work. David Murray reports research grants from NIHR Health Technology Assessment (HTA), specifically for TOPKAT (HTA 08/14/08), outside the submitted work; institutional grant and consultancy fees to the University of Oxford with Zimmer Biomet (Warsaw, IN, USA); and royalties from knee replacement-related patents. David J Beard reports grants from the NIHR HTA programme during the conduct of the study, specifically for TOPKAT. Sarah E Lamb was on the NIHR HTA Additional Capacity Funding Board (2012–15), HTA End of Life Care and Add-on Studies Board (2015), HTA Prioritisation Group Board (2010–15) and the HTA Trauma Board (2007–8). Rafael Pinedo-Villanueva reports personal fees from Mereo BioPharma Group plc (London, UK), Kyowa Kirin International (Galashiels, UK) and UCB Biopharma SPRL (Brussels, Belgium) outside the submitted work. Daniel Prieto-Alhambra reports NIHR HTA Funding Committee membership (November 2017–present); research grants from Amgen Inc. (Thousand Oaks, CA, USA), Johnson & Johnson (New Brunswick, NJ, USA), and UCB Biopharma SPRL; speaker services and advisory board membership fees paid to his department/research group from Amgen; and consultancy fees paid to his department/research group from UCB Biopharma SPRL. He also reports that Janssen Pharmaceutica (Beerse, Belgium), on behalf of Innovative Medicines Initiative-funded European Health Data Evidence Network and European Medical Information Framework consortiums, and Synapse Management Partners have supported internal training programmes organised by his department and open training programmes for external participants.